LONDON, United Kingdom, 5 January 2024 – Concr Ltd is pleased to announce a change in company leadership as Matt Foster passes the baton to Irina Babina, effective immediately.
Concr uses established computational frameworks from astrophysics to accurately predict patients’ therapeutic response and outcomes in cancer. These predictions also allow scientists to confidently identify and develop biomarkers of drug response to de-risk pivotal clinical trials and improve patient outcomes through effective stratification.
With an unwavering commitment to innovation in cancer care, Matt has been instrumental in steering Concr through significant milestones and achievements during his tenure. His dedication and vision have undeniably laid a robust foundation for our company's continued success. Matt will remain within the leadership team as the Chief Innovation Officer.
Irina’s promotion to the CEO position is a seamless transition marked by continuity, deep-rooted understanding, and first-hand experience within the organisation. She worked with Concr as a life sciences consultant before formally joining the team as Head of Strategy in 2022 and was promoted to Chief Business Officer following an oversubscribed seed round in 2023.
"Having worked with this remarkable team for over 2 years, I'm humbled by the confidence entrusted in me and the immense support of the team and the Board. I thoroughly enjoyed working side by side with Matt over the years and as CEO look forward to building upon the strong foundations he laid, embrace opportunities in our exciting field, and propel Concr to even greater heights." - said Dr Babina.
Concr’s Non-executive Chair Dr Tim Sparey commented “I’m delighted that Irina is stepping up into the CEO role to guide the business into the next, commercial phase of growth. I want to thank Matt for his vision and leadership these past couple of years and look forward to working with Irina and the team in 2024 and beyond.”
Please join us in extending a warm welcome to Irina as we step into this exciting new phase of growth at Concr.
For media inquiries or further information, please contact:
Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies. Concr’s unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate multi-modal tumour models. Using Concr’s cloud native platform – FarrSight® – researchers can computationally simulate clinical trials, make advanced predictions about biomarkers, and perform standard bioinformatics analyses directly. Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Parkwalk Advisors, Deep Science Ventures and SyndicateRoom.